Stock Events

Stock Events

Cellectis 

$3.41
150
-$0.07-1.87% Friday 19:59
+$0.02+0.44%Friday 20:00After hours

Statistics

Day High
3.42
Day Low
3.41
52W High
5.48
52W Low
2.35
Volume
2,172
Avg. Volume
-
Mkt Cap
342.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.26
-0.17
-0.08
0.01
Expected EPS
-0.20538740183
Actual EPS
N/A

Financials

-92.66%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
72.95MRevenue
-67.59MNet Income

Analyst Ratings

8.50Average Price Target
The highest estimate is 9.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLLS. It's not an investment recommendation.
TotalEnergies
13
TTE.PA
Microsoft
12
MSFT
Amazon
11
AMZN
AMD
11
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics is directly competing in the gene editing space, focusing on CRISPR/Cas9 technology, similar to Cellectis' TALEN technology for gene editing in therapeutics.
Editas Medicine
EDIT
Mkt Cap477.63M
Editas Medicine operates in the genome editing field, utilizing CRISPR technology to modify genes, directly competing with Cellectis' gene editing therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a competitor in the CRISPR/Cas9 genome editing technology, offering therapies that could potentially overlap with Cellectis' market in gene-edited treatments.
Allogene Therapeutics
ALLO
Mkt Cap722.08M
Allogene Therapeutics specializes in allogeneic CAR T-cell therapies, which competes with Cellectis' approach to off-the-shelf CAR T-cell products.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the CAR T-cell therapy space, directly challenging Cellectis' CAR T-cell product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, a field that indirectly competes with Cellectis' gene editing technologies for therapeutic applications.
Pfizer
PFE
Mkt Cap159.99B
Pfizer is involved in biopharmaceuticals, including investments in gene therapy and immunotherapy, areas that compete with Cellectis' focus on gene-edited immunotherapies.
Novartis
NVS
Mkt Cap301.95B
Novartis has a strong presence in gene therapy and CAR T-cell therapy, including the first FDA-approved CAR T-cell therapy, competing with Cellectis in the advanced therapy medicinal products space.

About

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Show more...
CEO
Andre Choulika
Employees
229
Country
France
ISIN
US15117K1034
WKN
000A14QZE

Listings

STU
DE
ZVAA.STU
STU
DE
ZVA.STU
F
DE
ZVAA.F
MU
DE
ZVA.MU

0 Comments

Share your thoughts

FAQ

What is Cellectis stock price today?▼
The current price of CLLS is $3.41 USD — it has decreased by -1.87% in the past 24 hours. Watch Cellectis stock price performance more closely on the chart.
What is Cellectis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cellectis stocks are traded under the ticker CLLS.
Is Cellectis stock price growing?▼
CLLS stock has risen by +9.49% compared to the previous week, the month change is a +19.89% rise, over the last year Cellectis has showed a +19.47% increase.
What is Cellectis market cap?▼
Today Cellectis has the market capitalization of 342.88M
When is the next Cellectis earnings date?▼
Cellectis is going to release the next earnings report on November 09, 2026.
What were Cellectis earnings last quarter?▼
CLLS earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.26 USD resulting in a +15.98% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cellectis revenue for the last year?▼
Cellectis revenue for the last year amounts to 72.95M USD.
What is Cellectis net income for the last year?▼
CLLS net income for the last year is -67.59M USD.
How many employees does Cellectis have?▼
As of August 24, 2026, the company has 229 employees.
In which sector is Cellectis located?▼
Cellectis operates in the Health & Wellness sector.
When did Cellectis complete a stock split?▼
Cellectis has not had any recent stock splits.
Where is Cellectis headquartered?▼
Cellectis is headquartered in Paris, France.